Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
First Claim
Patent Images
1. A method for treating nephrotic syndrome, wherein the nephrotic syndrome is minimal change disease (MCD), membranous nephropathy (MN) and/or focal segmental glomerulosclerosis (FSGS);
- or caused by or associated with minimal change disease (MCD), membranous nephropathy (MN) and/or focal segmental glomerulosclerosis (FSGS), the method comprising administering linagliptin to a patient in need thereof, optionally in combination with one or more other active agents.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
303 Citations
13 Claims
-
1. A method for treating nephrotic syndrome, wherein the nephrotic syndrome is minimal change disease (MCD), membranous nephropathy (MN) and/or focal segmental glomerulosclerosis (FSGS);
- or caused by or associated with minimal change disease (MCD), membranous nephropathy (MN) and/or focal segmental glomerulosclerosis (FSGS), the method comprising administering linagliptin to a patient in need thereof, optionally in combination with one or more other active agents.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
Specification